Acentrus Specialty, a national network of health systems and hospitals, has finalized an agreement with Puma Biotechnology (NASDAQ:PBYI) to provide qualified Acentrus clients access to Puma’s Nerlynx (neratinib), a kinase inhibitor indicated for the treatment of breast cancer.
Participation in Acentrus is open to hospital organizations of all sizes, types and affiliations. There is no cost for an organization to join the Acentrus network.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.